Does paraoxonase play a role in susceptibility to cardiovascular disease?

被引:100
作者
Aviram, M [1 ]
机构
[1] Technion Israel Inst Technol, Rappaport Family Inst Res Med Sci, Tech Fac Med, Lipid Res Lab, IL-31096 Haifa, Israel
[2] Rambam Med Ctr, Haifa, Israel
来源
MOLECULAR MEDICINE TODAY | 1999年 / 5卷 / 09期
关键词
D O I
10.1016/S1357-4310(99)01546-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human serum paraoxonase (PON1) is an esterase that is bound to high-density lipoproteins (HDLs). It can hydrolyze organophosphates and its activity is inversely related to atherosclerosis. Some studies also suggest that a relationship exists between polymorphisms of the gene that encodes paraoxonase and coronary heart disease (CHD), whereas other studies, in different populations, have not found such an association. One mechanism by which certain PON1 allozymes might protect against atherosclerosis is by inhibition of the oxidation of HDL and low-density lipoprotein (LDL). Experimental studies suggest that this protection is associated with the ability of PON1 to hydrolyze specific lipid peroxides in oxidized lipoproteins. interventions that preserve or enhance PON1 activity, as well as manipulations of Pont polymorphisms, might help delay the onset of CHD.
引用
收藏
页码:381 / 386
页数:6
相关论文
共 34 条
  • [1] The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns
    Antikainen, M
    Murtomaki, S
    Syvanne, M
    Pahlman, R
    Tahvanainen, E
    Jauhiainen, M
    Frick, MH
    Ehnholm, C
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (04) : 883 - 885
  • [2] LDL oxidation by arterial wall macrophages depends on the oxidative status in the lipoprotein and in the cells: Role of prooxidants vs. antioxidants
    Aviram, M
    Fuhrman, B
    [J]. MOLECULAR AND CELLULAR BIOCHEMISTRY, 1998, 188 (1-2) : 149 - 159
  • [3] Aviram M, 1996, EUR J CLIN CHEM CLIN, V34, P599
  • [4] Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities - Selective action of human paraoxonase allozymes Q and R
    Aviram, M
    Billecke, S
    Sorenson, R
    Bisgaier, C
    Newton, R
    Rosenblat, M
    Erogul, J
    Hsu, C
    Dunlop, C
    La Du, B
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (10) : 1617 - 1624
  • [5] Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants
    Aviram, M
    Rosenblat, M
    Billecke, S
    Erogul, J
    Sorenson, R
    Bisgaier, CL
    Newton, RS
    La Du, B
    [J]. FREE RADICAL BIOLOGY AND MEDICINE, 1999, 26 (7-8) : 892 - 904
  • [6] Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions - A possible peroxidative role for paraoxonase
    Aviram, M
    Rosenblat, M
    Bisgaier, CL
    Newton, RS
    Primo-Parmo, SL
    La Du, BN
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (08) : 1581 - 1590
  • [7] AVIRAM M, 1999, CURR INT CARDIOL REP, V1, P66
  • [8] Lack of association between carotid intima-media thickness and paraoxonase gene polymorphism in non-insulin dependent diabetes mellitus
    Cao, HB
    Girard-Globa, A
    Serusclat, A
    Bernard, S
    Bondon, P
    Picard, S
    Berthezene, F
    Moulin, P
    [J]. ATHEROSCLEROSIS, 1998, 138 (02) : 361 - 366
  • [9] The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin
    Davies, HG
    Richter, RJ
    Keifer, M
    Broomfield, CA
    Sowalla, J
    Furlong, CE
    [J]. NATURE GENETICS, 1996, 14 (03) : 334 - 336
  • [10] Increased uptake of LDL by oxidized macrophages is the result of an initial enhanced LDL receptor activity and of a further progressive oxidation of LDL
    Fuhrman, B
    Judith, O
    Keidar, S
    BenYaish, L
    Kaplan, M
    Aviram, M
    [J]. FREE RADICAL BIOLOGY AND MEDICINE, 1997, 23 (01) : 34 - 46